Thursday, July 19, 2012
松山湖台湾高科技园 硬體規劃!
台灣醫療環境惡化? 監察院糾正行政院 !
中国生物仿制药行业扩容仍存在阻力
"假發票"引討論 國科會"鬆綁與課責"
兩性奧秘:性夢背後的真實想法
長期背痛可能和腦有關
医药联盟创新促制药行业整合升级
工作狂 可能與大腦的多巴胺分泌量和位置有關 ?
台灣API 廠因產業鏈改變 進入國際供應商行列!!
科研經費審查放寬浮報重罰
2012-07-19 21:30:504個月前爆發科研經費核銷用假發票,行政院國科會主委朱敬一19日表示,科研經費8月起將實施新作法,審查彈性放寬;若浮報,對個人停權、扣浮報額的1到3倍經費。中央社19日報導,朱敬一指出,國科會今天修訂完成「補助專題研究計畫作業要點」與「補助專題研究計畫經費處理原則」部分規定修正案,8月起實施。他強調,這次修正有4大重點,首先是放寬專題研究計畫業務費、研究設備費與國外差旅費3大項目的流用比例,將從現行各大項流入20%、流出30%,放寬至流入及流出都50%,超過此新制比例,才需要報國科會核准;此彈性度參考德國、美國、日本等國,與歐美國家大致相當。其次,國科會只管上述3大主經費項目的新增與流用,其餘主項目內細項與經費調整,由校方認定合理性。他舉例,像是耗材、人力等細項的合理性認定;但是計畫結束後,學校必須繳交變更報表,方得結案。第3點,取消經費細目例示,以免誤導僵化認定內容;將來與研究相關的支出,授權學研機構認定。第4點為新增規範,基於前述要點彈性已經放寬,若涉及浮報虛報或浮鑑認定,國科會得視情況減扣申請機構管理費,幅度得為浮報虛報總額的1到3倍。朱敬一強調,第4點的扣款是新制。他說,假如浮報一只單價新台幣2000元的訂書機,並買了30只,則會扣款機構管理費;若是浮報購買一顆鑽石,則會對當事人停權(不再獲研究經費補助),並要送檢調偵辦。朱敬一重申,「我們是勇敢的!新訂定的作法,不一定就是最好的,若彈性要再放寬,會放寬,需要更嚴格,會更嚴格,要先試用。」【中央網路報】
遠距雲端照護 日夜監控糖尿病
【中央社╱台北15日電】 2012.07.15 04:20 pm 羅東聖母醫院和保全業者合作,遠距照護糖尿病患,健康資訊上雲端,有的病患免於低血糖昏倒危險,也有病患被捉到竄改血糖數值,進而調整藥物及平日飲食,成效良好。 羅東聖母醫院新陳代謝科主任陳白蓮指出,有位病人連續多日量測,早上空腹血糖值約100,晚上飆到300至400,如果日夜維持相同的藥量,很容易白天血糖太低而昏迷或休克。透過雲端報表,醫師調整病人的藥量,更有效控制血糖。 另一名患者今年3月報表顯示,多日處於低血糖,但是保全客服紀錄發現病患並無不適且食慾正常,醫師推斷患者可能是降血糖藥過量,主動聯繫病患家屬,建議將血糖藥減量,並增加血糖量測次數,有需要時也可以提早回診。 陳白蓮指出,慢性病友最麻煩的就是難以定期記錄血糖指數,甚至會造假。常遇到老人家,回診前竄改血糖紀錄,或平時不注意飲食,回診前幾天才做個樣子。雲端健康照護搭起醫院與病友的橋梁,能幫助醫師診斷,也幫病人監控病情。 這套「醫療照護雲」遠距醫療照護系統,由保全業者聘請的合格護理師與醫院社工組成服務中心,創新糖尿病照護模式,24小時全年無休提供諮詢與關懷,目標是促進病友自我健康管理,降低糖尿病合併症,減少住院及門診次數。 據中興保全表示,當雲端數據顯示患者血糖量測或其他生理指數出現異常指數時,會立即聯繫病人,病人到門診時,想不起當時異常狀況的原因也無妨,因為護理客服人員的紀錄,可協助醫師診斷病情。 【2012/07/15 中央社】
腦死判定擬放寬 足月嬰可器捐
【聯合晚報╱記者黃玉芳/台北報導】 2012.07.15 02:28 pm 衛生署自93年公布「腦死判定準則」以來,3歲以下嬰幼兒沒有納入,引發爭議。最近衛生署委託器官捐贈移植登錄中心,邀集專家學者再度開會,終於對解除腦死判定年齡限制有了共識,只要是足月生產的新生兒,經過一定程序,也可以執行腦死判定。 衛生署醫事處科長呂念慈表示,衛生署擬放寬限制,未來只要是經媽媽懷孕滿37周、足月生產的新生兒,不幸陷入深度昏迷、或是腦部結構損壞無法復原,可由小兒專科醫師執行腦死判定。不過昏迷原因需排除藥物中毒、體溫過低等因素。 同時考量嬰幼兒的潛在修復能力較強,雖然嬰幼兒腦定判定跟成人一樣,也需經兩次的腦死判定,但成人兩次腦死判定只需間隔4小時,嬰幼兒的觀察時間拉長、更為嚴謹,學者專家討論共識,1至3歲需間隔12小時、1歲以下更需間隔24小時,才能做第二次腦死判定。 衛生署表示,「腦死判定準則」修正草案,預計將於8月定案,正式對外預告、公告修正草案內容,完成相關的立法程序。 器官捐贈移植登錄中心統計,國內等待心、肝等各種器官移植的小小孩,一年雖不到10人,但受限腦死判定才能摘取器官的法令限制,3歲以下嬰幼兒幾乎等不到器捐。 前台灣小兒神經醫學會理事長、國泰醫院副院長洪焜隆表示,過去擔心嬰幼兒對腦部缺氧的耐受性較高,近十年來雖有討論,但一直不敢替嬰幼兒進行腦死判定。但臨床上遇到明明已經腦死,卻苦無法源依據,不僅可能流失器官捐贈的契機,小小孩只能繼續住在加護病房一到兩個月後過世,期間也衍生無效醫療。 去年美國已同意將新生兒納入腦死判定,國內也終於達成共識。洪焜隆說,每個孩子都是父母的心頭肉,可能捨不得判定腦死的小寶貝捐出器官,但至少勸募人員可以試著介入,讓腦死小孩的器官延續其他孩子的生命。 亞東醫院外科部主任陳芸也說,除了心、肝等器官外,小腸移植已被衛生署列為常規手術,由於短腸症患者六成是幼兒,一出生就只能靠著靜脈注射攝取營養,長期注射容易造成感染、肝脾腫大、黃疸、出血,若要移植救命,必須要有尺寸、長度適合的腸子,放寬法令後,小小患者有機會重拾生機。 【2012/07/15 聯合晚報】
常常莫名焦慮 老化速度恐加快
醫院人力失衡 3年300億解決
【聯合報╱記者李順德/台北報導】 2012.07.14 02:54 am 行政院長陳冲昨天原則同意衛生署長邱文達所提三年三百億預算,解決醫界五大科人力失衡問題。另外,將於二○一四年實施的公費醫學生返偏鄉服務新制,未來可由衛生署指定科別執業,以因應各科醫師人力需求。 邱文達昨天是提出「提高五大科執業意願、降低醫療糾紛風險策略」報告。衛生署建議,提高內外婦兒及急診等五科全民健保給付標準、增加住院醫師津貼、調整五科醫師訓練員額、充實五科輔助醫療人力、強化畢業後全科及五科訓練方向。 財源來自公務預算、醫發基金、健保總額成長,陳冲請衛生署整合醫療資源,提減少浪費的具體方法。 邱文達說,衛生署將於十月一日試辦生育事故救濟制度,提供最高新台幣二百萬元救濟給付補助。衛生署也研議修醫療法,使醫療過失刑責合理化。台灣醫生因醫療過失被判刑責是世界上罕見,這也是國內醫生最大的壓力。 邱文達說,二○一四年將實施偏遠地區公費醫學生新制(不限落籍地),有限制選科;陳冲指示,未來可由衛生署視社會當時各科醫師人力分布狀況,指定公費生選擇國家需要的科別執業。 【2012/07/14 聯合報】
China Biotech In Review: Deals, Trials And Regulations
July 15, 2012|includes: ALNY, OCLS Deals and TransactionsAscletis Pharma, a US-China JV that made headlines one year ago when it announced $100 million in initial startup capital, in-licensed China rights to its first drug candidate, an innovative RNAi molecule from Alnylam Pharma (NSDQ: ALNY) (see story). ALN-VSP is being developed for liver cancers including hepatocellular carcinoma (HC)). Ascletis will have exclusive rights for ALN-VSP in China, Hong Kong, Macau and Taiwan. Alnylam will retain rights to the drug for the rest of the world.Yunnan Walvax Biotech (SHE: 300142) obtained a 51% stake in Shanghai Fengmao Biotech. Walvax, previously known as a vaccine maker, will establish subsidiaries of Fengmao to produce five monoclonal antibodies and a sustained-release version of the anemia treatment EPO. Walvax will invest $16 million in cash, while other investors will contribute a monoclonal technology valued at $14.6 million.HAO Capital, a Beijing-headquartered private equity firm, teamed up with TCL Group, a consumer electronics company that has a medical device subsidiary, to form a JV called TCL Healthcare. The JV will target the high-end diagnostic imaging market in China. The capitalization of the JV was not disclosed.Siegfried Holding (SIX: SFZN), a Swiss CMO, is building an API and intermediates production facility in Nantong. The construction is being supported by the Nantong Economic and Technological Development Area (NETDA). Siegfried said additional land at the site may be used in the future for building a finished drug facility.
Trials and ApprovalsOculus Innovative Sciences (NSDQ: OCLS) of California received SFDA approval for Microcyn Hydrogel, a topical treatment for moistening, repairing and healing of acute and chronic wounds (see story). With the approval in hand, Shanghai Sunvic, the China partner of Oculus, will launch the product in Q3 of 2012, marketing Microcyn Hydrogel in both the OTC and professional healthcare markets in China.
Government and RegulatoryThe SFDA has issued new regulations governing the purity and safety of excipients, the pharmacologically inactive substances that drugmakers add to stabilize or deliver a drug's active ingredients. The new rules, which go into effect on October 1, place responsibility for the safety of the excipient on the drug company that uses it. The regulations also require excipient makers to test their products and prove they meet all specifications.
Disclosure: none.
海外就醫問題多 大陸就醫最怕「門診黃牛」
時間:2012/7/19 17:59 撰稿‧編輯:沈雅雯 新聞引據: 採訪暑假來到,民眾出國旅遊人數大增,在海外遇到醫療問題的情況也不少。根據國際SOS緊急救援組織統計,去年共接獲12萬5千通求援電話。其中,最常發生就醫問題是「不知道如何溝通陳述病況」;而民眾最害怕生病求醫的國家則是中國大陸,最擔心碰上「門診黃牛」。每個國家的醫療情況與就醫規定大不相同,如果在海外生病,更是令人感到困擾無助。根據國際SOS緊急救援組織統計,去年一年共接到12萬5千通海外醫療案件求援電話,其中,民眾最常碰到的問題是「不知道如何溝通陳述病況」」、「不放心醫療環境衛生」以及「不知道該找哪家醫院或專科」。調查也指出,民眾最怕生病就醫的國家,前5名分別是中國大陸、越南、印尼、美國和東歐,除了害怕環境衛生不良、醫療設備不佳外,部分國家的醫療費用太高也是主因。國際SOS協調醫師陳婉琳則說,每個國家情況不同,民眾可能因為不知情而花了冤枉錢,甚至引發嚴重糾紛。例如在越南流行塞紅包賄賂醫護人員;在大陸,則常常有「門診黃牛」搶掛號,再以高價叫賣。她說:『(原音)叫賣的價碼常常是門診掛號費的5、6倍,假設是名醫、專家甚至會高到10倍、20倍,這個門診黃牛叫賣號碼牌會影響到很多人在當地就醫的權益。』國際SOS總經理陳楷植建議,在海外就醫最好尋求能溝通的醫師,不要因為心急,什麼都說「YES」,出國前也要先準備好急難救助電話,遇到問題時可以隨時尋求協助。
科技大老攻雲端 上天下海
Choosing Sunscreen?
How to Decode the Labels Dermatologist explains what SPF numbers really mean, how much protection to use and when By Robert Preidt Saturday, July 14, 2012 SATURDAY, July 14 (HealthDay News) -- You may know that it's important to protect your skin when you're outdoors this summer, but you need to know how to pick the correct sunscreen and how to apply it, the American Academy of Dermatology says. "Consumers can be overwhelmed by the large number of sunscreen products available and because of that they avoid using sunscreen all together, resulting in sunburn and overexposure to the sun's ultraviolet (UV) radiation," dermatologist Dr. Henry Lim said in an AAD news release. "Dermatologists can provide the public with the information they need to make smart choices when it comes to sun protection, which can help reduce their risk for skin cancer, and keep their skin looking healthy and youthful," he added. The AAD says you should read the label on sunscreen products and use only those that offer: Broad-spectrum coverage (label may say "broad spectrum," "protects against UVA/UVB" or "UVA/UVB protection"). SPF of 30 or higher. The AAD also recommends that you: re-apply sunscreen every two hours when outdoors; find shade whenever your shadow appears to be shorter than you are; wear protective clothing, including long sleeves, pants, wide-brimmed hat and sunglasses. An AAD online survey found that many people are still confused about SPF numbers and how to use sunscreen correctly. Only 18 percent of respondents knew that a sunscreen with SPF 30 does not provide twice the protection of an SPF 15, and only 28 percent of respondents who said they sometimes or always use sunscreen reapplied sunscreen every two hours. UV protection does not increased proportionately with a designated SPF number, Lim said. An SPF 30 screens out 97 percent of UV rays, an SPF 15 screens 93 percent of UV rays, and an SPF 2 screens 50 percent of UV rays, he explained. Lim also noted that not applying enough sunscreen or not covering all exposed areas may result in a lower SPF than a sunscreen offers. "For adequate protection, sunscreens are best applied 15 minutes prior to going outside, and re-applied every two hours or immediately after swimming or sweating," Lim said. "Research demonstrates that most people only apply 25 to 50 percent of the recommended amount of sunscreen, which is one ounce for the entire body or enough to fill a shot glass. The relationship between SPF and amount applied is not a linear one. For example, if only half the proper amount of SPF 15 is applied, the actual in-use SPF would be approximately 5, which is then inadequate protection." SOURCE: American Academy of Dermatology, news release, June 14, 2012 HealthDay
冬蟲夏草培養基 變降低憂鬱保健品!
海大教授開發「忘憂飲」 廢米飯變保健品2012/07/19 ■徐谷楨■ 現代人失眠問題普遍,台灣海洋大學食品科學系教授蔡國珍利用廢棄米飯培養基,研發一款乳酸菌發酵飲品「忘憂飲」,效果號稱媲美知名抗憂鬱藥物百憂解,而且經動物實驗,不會產生食欲不佳的副作用,正申請專利中。蔡國珍表示,一般業者「收割」冬蟲夏草之後,剩下的米飯培養基通常沒有什麼價值,但是它含有少許冬蟲夏草菌絲,加入特殊乳酸菌發酵,可產生高量的胺基丁酸(GABA),藉此研發抗憂鬱活性的乳酸發酵飲品,讓廢棄米基變身高價的保健食品。蔡國珍採用的特殊乳酸菌是來自從魚的腸道中分離出來的乳酸菌株,具有耐低溫儲存、耐胃酸與腸胃道環境的特性,解決了一般乳酸菌不耐低溫與人體胃酸與膽鹽的缺點,同時這株乳酸菌也是人體的益生菌,在攝氏20度到37度可生長良好,可生產高量的GABA。蔡國珍指出,GABA是人類中樞神經系統所分泌的抑制神經傳導物質,根據過去研究顯示,GABA對於血壓、血糖的調節,以及精神安撫、降低憂鬱程度等有幫助。她的研究團隊已經開發出添加桂圓、紅棗的高GABA乳酸飲品,風味不錯
台灣百靈佳殷格翰 也賣保健品!! (人蔘維他命)
台灣百靈佳殷格翰藥廠引進 歐洲暢銷品牌福馬康人蔘維他命2012/07/19 【台北訊】全球前20大藥廠百靈佳殷格翰,為讓消費者能更方便地補充完整營養素,特自歐洲引進暢銷品牌福馬康 人蔘維他命,在全省屈臣氏、康是美通路藥局上市。 福馬康人蔘維他命產品經理羅芝青表示,蔘製品中的人蔘皂 含量若不足夠,不但無法達到預期補充效果,不良的人蔘品種、過度噴灑農藥、快速收成或不精密的萃取製程,反而暗藏傷害人體健康的風險。有鑑於此,福馬康人蔘維他命在製程中制定嚴格的選種、種植、萃取等SOP步驟:嚴選有機栽種六年以上的上選高麗蔘種Panax Ginseng C.A. Meyer,以真空冷凍技術乾燥蔘根水分,再加上專利「定性定量」製成技術(Standardized Ginseng Extract),讓每一顆福馬康? 人蔘維他命活力膠囊都含有一定劑量的人蔘精華,為消費者的健康嚴密把關,此產品為軟膠囊形態,不僅好吞服,也易被吸收。 (陳碧雲)
台灣第一"合法"魚類疫苗(石斑魚疫苗)!!!
石斑魚疫苗問世 有注有保庇2012/07/19【台北訊】針對石斑魚養殖產業的剋星「石斑虹彩病毒感染症」所研發的首支疫苗,經廣泛試用結果,可讓龍膽石斑在免疫後5個月活存率可達9成以上,青斑則可達7成5以上,可提高我國石斑魚產業的出口競爭力。 農委會家畜衛生試驗所助理研究員黃淑敏表示,針對好發於吋苗到後段成魚養成階段的石斑魚虹彩病毒,所研發的石斑魚虹彩病毒不活化疫苗,去年已成為國內首支合法登記使用的魚類疫苗,26日將在生物科技大展農業科技主題館展出。農委會指出,我國水產養殖業的技術先進,產值高,尤其近年石斑魚等高經濟價值的魚種因為政府的政策推動及ECFA的簽訂而擴大市場,前景看好。不過,石斑魚養殖產業有二大剋星,分別為石班虹彩病毒感染症、神經壞死病毒,可成高達八成的損失,發展疫苗是現今最好的防疫對策。黃淑敏透露,有個知名科技公司的工程師放棄高薪工作,轉而投入石斑魚養殖業,還為了幫石斑施打疫苗,研發一台可以自動為魚類施打疫苗的機器,共同守護我國石班魚養殖產業,這台機器也將同步於生技展展出。
台灣創新生技? 何謂創新???
Seaweed toothpaste stops tooth decay ?
Saturday, July 14, 2012 by: PF Louis (NaturalNews) Brushing and flossing doesn't always keep you out of the dentist's chair, a chair we all need to avoid. Amalgams inserted into cavities are loaded with toxic mercury that leaks into our bodies. Root canals have been discovered to be the root of some chronic illnesses. (Natural News, source below). Of course, fluoride doesn't help prevent tooth decay. Instead, it contributes to bad physical and mental health and lowers I.Q. while diminishing will power. It's toxic and actually causes dental fluorosis, decaying tooth enamel that will put you back into that dental chair. So what to do to avoid the barbarism of modern dentistry? It appears that sea life may come to the rescue. A group of UK scientists are experimenting with enzymes extracted from seaweed microbes that may be able to remove the microbes in dental plaque. The Newcastle University research team had originally pursued this line of research into seaweed's Bacillus lichenifromis for the ship industry to see if these microbes would help clean ships' hulls without going into expensive dry dock maintenance that also takes a ship's time away from the sea. Actually, it's not the microbes themselves that deliver the cleansing. It's the enzymes they produce. This type of enzyme has to come from raw seaweed. Heat destroys enzymes.
From seawater to ship hulls to dental plaque Dr. Nick Jakubovics of the Newcastle University School of Dental Sciences discovered how these same enzymes produced by seaweed microbes could eliminate plaque on, between, and behind the teeth if utilized in an oral mouthwash or toothpaste. Dr. Jakubovics explained: "Plaque on your teeth is made up of bacteria which join together to colonize an area ... scrubbing off the plaque containing bacteria is not always effective ... We found this enzyme can remove some of these undesirable bacteria from plaque." Plaque is made up from lots of decaying bacteria. When those cells die, their DNA leaks out to form a biofilm that sticks to teeth. The dental research into seaweed enzyme producing microbes focuses on eliminating the need to eliminate plaque entirely. Instead, the idea is to simply remove the bacteria like Streptococcus mutans that actually cause tooth decay. Dr. Jakubovics and his team intend to present their findings to the UK's Society of Applied Microbiology. Dr. Jakubovics comes across in a radio interview as very conservative with how long it may take to go from research to market with his findings. Perhaps because he's familiar with the UK's process that rivals the USA's FDA hoops for approval. The short radio interview is available in the BBC Report below. Some of those hoops could be provided by dental profession groups' desire to not reduce office visits that require laborious plaque removal work. Worse yet, actually reducing cavities would eliminate a lot of dental business. In the UK's system of socialized medicine, that would logically reduce the national economic burden of health care. But logic isn't always worshiped by governments and egoistic medical groups, as evidenced by recent manic attempts to remove vastly less expensive homeopathy health care from England's medical system (http://www.naturalnews.co/034164_medical_monopoly_homeopathy.html). Here in the USA, that could result in even more opposition from the American Dental Association (AMA) bureaucrats who control the dental trade union to keep dentists in business. Even as the AMA publicly supports water fluoridation from industrial waste fluorides to prevent tooth decay, there is no evidence of less tooth decay from toxic public water fluoridation. Why should dentists even really want less tooth decay? How could they pay their staff, lease all that expensive dental apparatus, and buy more BMWs to park in their McMansions?
中興新村高等研究園區 拼文化商機!!!!
大咖青睞睞中興新村成文創產業新星 2012-07-19 01:39 中國時報 【盧金足/台中報導】國際大導演侯孝賢、霹靂布袋戲、明華園歌仔戲,近來都到中興新村高等研究園區投石問路,七十二公頃用地,除卅五公頃規畫為科技園區,將釋出十五公頃作為全台灣最大規模文創園區,日月潭是中部明珠,中科發豪語,要讓中興新村成文創產業最閃亮的鑽石。中興新村轉型為高等研究園區,一般人都以為是中科的新科技重鎮,殊不知,這座園區也正在進行一場文創產業的大遷徙。「侯孝賢導演親自來中興新村,看到以前省政府留下的辦公廳舍、宿舍、綠樹扶蔭環境,很有興趣在這裡蓋片廠和電影中心,推動台灣大型影城」,中科管理局長楊文科說,為吸引文創業者進駐中興新村,提供十五公頃土地,每平方公尺土地、每月租金才六.三元,對影視業者很有誘因。楊文科說,台灣文創產業「大咖」,紛紛來中興新村考察,驚嘆這裡的風土人文,連知名史艷文霹靂布袋戲都有意來這裡興建攝影棚和博物館、明華園歌仔戲更展現進駐意願,3D動漫、遊戲集團也紛紛想來中興新村搶頭香。中科希望大陸觀光客來台遊覽日月潭、阿里山,一定要來中興新村欣賞台灣原汁原味的布袋戲和歌仔戲,人潮帶來錢潮,文創成為全台朝聖重鎮。為營造「文化是門好生意」商機,中科也正研擬開國際標,由國際級建築師來中興新村興建五星級大飯店,讓國內外觀光客遊寶島,會以在中興新村吃喝玩樂列為第一選擇。
Less time sitting can add two healthy years to your life
Saturday, July 14, 2012 by: John Phillip (NaturalNews) Many people believe they must engage in strenuous physical activity to achieve optimal fitness and prevent illness. While exercise is certainly important to health, new research provides a different perspective about the negative effects of sitting for extended periods and how we can make small changes to potentially increase our natural lifespan. Researchers gleaning data from the National Health and Nutrition Examination Survey (NHANES) have published the result of a study in the journal BMJ Open, that explains how restricting the amount of time spent seated every day to fewer than three hours might boost the life expectancy of US adults by an extra two years. Additionally, they have found that cutting down TV viewing to fewer than two hours every day might extend life by almost 1.4 years. In the past, studies have implicated sitting for extended periods and watching too much television with illnesses including diabetes, heart disease and stroke. This study is the first to directly link the sedentary lifestyle habits of more than 167,000 people with relative risk of developing or dying from a chronic illness. Researchers pooled data from five relevant studies to arrive at their startling conclusion.
Walking or standing a few minutes each hour may help extend lifespan in aging adults The scientists pooled all relevant data to develop a statistical tool known as a population attributable fraction (PAF). The PAF is an estimate of the theoretical effects of a risk factor on a population, rather than an individual marker, necessary to calculate the number of deaths associated with time spent sitting down. The researchers determined the PAFs for deaths from all causes linked to sitting time and TV viewing were 27 percent and 19 percent, respectively. By extrapolating the PAF statistics, the study team determined that cutting the amount of time spent sitting down every day to under three hours would add an extra two years to life expectancy. In a similar manner, restricting time spent watching TV to under two hours daily would extend life expectancy by an extra 1.38 years. These results are significant because many aging adults spend extended periods of time sitting or lying down as they watch television. Standing or walking for several minutes each hour may provide protection against vascular and metabolic dysfunction, the underlying processes behind the explosion in new cases of cardiovascular disease, stroke and diabetes in our aging population.
你覺得自己臉太大嗎?
調查:整形最憂落差大 2012-07-19 新聞速報 中央社開業整形專科醫師張博全今天表示,傳統整形是民眾拿著藝人照要求醫師複製,往往會出現撞臉或整過頭,調查顯示8成不考慮整形手術的原因是,擔心術後落差。一份今年6月15日到7月15日「2012立體小顏大調查」顯示,透過網路問卷調查1321名民眾,超過7成民眾認為自己臉太大,超過5成表示外表會影響自信心,11%擔心影響求職,然而整形也非所有民眾都能接受,除考量醫療品質外,近8成不考慮手術的原因在於擔心術後落差大。張博全表示,許多民眾都以藝人臉形為範本到醫療院所聽聽專科醫師意見,自己想像術後可能會出現的樣貌,往往在手術結束時,期待又害怕的心情就在揭曉那一刻,一旦與原本想像有落差時,也無法再重來。拿藝人照的民眾對於整形有過度期望,開業整形專科醫師鄭紹隆表示,藝人照的訊息可使醫師知道患者個性,當作參考,不過每個人臉形不同,整形是要依個人條件去改造成比較好的,需配合整個臉的線條讓臉部和諧。1010719
Aetna Upgrades iTriage Consumer Health Care App for the iPad
Posted on Wednesday Jun 20th 2012 by Brian T. Horowitz. Aetna has announced that its health care app iTriage will run as a native application on the iPad, taking full advantage of its high-resolution Retina display. Aetna has announced that it has optimized the company's iTriage health resource for the Apple iPad with a new native app. iTriage is a Web-based service that allows consumers to research symptoms, look up medical providers and schedule appointments. It provides information on diseases and medical procedures, and uses GPS to direct patients to providers' facilities. The company redesigned the app to fit the full high-resolution display of the Apple tablet, said Dan Tucker, iTriage product manager, who blogged about the new iPad version.
The app can take full advantage of the iPad's Retina display, according to Aetna. iTriage is designed on the iPad in a "sweeping panel" format, in which one column lists a patient's condition, such as a puncture wound, and the middle column lists the definition. The third column shows a list of medications that can treat the problem, a location where patients can find treatment and an estimate of services for care. In addition, the iPhone iTriage version now allows consumers to search for providers by category, including Emergency Departments, Urgent Care, Retail Clinics, Physicians, Pharmacies and Additional Outpatient Clinics. Aetna acquired Healthagen, the developer of iTriage, Dec. 15, 2011, and relaunched iTriage March 5. The company announced the new iPad version June 19. The app's Symptom-to-Provider feature leads users through a question-and-answer process of connecting symptoms and causes as well as finding providers. iTriage is the first software tool on Aetna's open-data platform called CarePass, which allows consumers to share data and manage their health across applications using a single sign-on. CarePass is open to any insurance carrier, consumer or third party, Mark Bertolini, Aetna's chairman and CEO, announced at a March 5 relaunch event for iTriage. An iPhone app for iTriage launched in March 2009. Since then, the app has reached 6 million downloads, according to Aetna. "Our vision is to help the world make better health care decisions," Dr. Peter Hudson, co-founder and CEO of iTriage, said in a statement. "Expanding the availability and functionality of iTriage on the devices that consumers are increasingly using helps more people take control of and conveniently manage their health care decisions." iTriage allows patients to rate providers using technology from Vitals.com. The app also now features an ER Check-In feature for hospitals and an Early Check-In capability for urgent care clinics. Hudson and Dr. Wayne Guerra, iTriage's co-founder and chief medical officer, developed the service in 2008. On June 19, Aetna also announced that it would integrate its wellness platform Resources for Living with Consult A Doctor's telehealth platform, which allows patients to connect with doctors using video, phone or email. The combined platform, Consult A Doctor Plus, offers 24/7 phone consultations, patient advocacy bill review and mediation, electronic health record (EHR) access along with legal and financial consulting. "With Consult A Doctor Plus, we are able to work hand-in-hand with Aetna to reach beyond traditional, primary care settings and explore new opportunities within the telemedicine spectrum of health care," said Wolf Shlagman, founder and CEO of Consult A Doctor, in a statement.
睾酮疗法可增强心衰患者运动能力 !!!
发布时间:2012-7-19 来源:爱唯医学 低睾酮是心力衰竭(HF)患者运动能力降低和不良临床结果的一个独立的预测因子。研究者试图确定睾酮疗法是否能改善稳定性慢性心衰患者的运动能力。研究者检索了1980~2010年间Medline、Embase、Web of Science和Cochrane对照试验中心注册库的数据,纳入报道睾酮对心衰患者运动能力影响的随机对照试验(RCT)。最终确定了4项试验(n=198;男性占84%;平均年龄67岁)。试验采用6分钟步行测试(2项RCT)、增量往返步行试验(2项RCT)或峰值氧耗量(2项RCT)来评估治疗52周后的运动能力。结果显示,相对于安慰剂,睾酮疗法与运动能力明显改善相关。睾酮组相对于安慰剂组在6分钟步行测试、增量往返步行试验和峰值氧耗量方面的平均增量分别是54.0米(95%CI,43.0~65.0)、46.7米(95%CI,12.6~80.9)和2.70 ml/kg·min(95%CI,2.68~2.72)。采用汇总SDs单元检测,睾酮疗法与运动能力明显增强相关(净效应,0.52 SD;95%CI,0.10~0.94)。无明显心血管不良事件。研究者总结认为,睾酮似乎是改善心衰患者功能能力的一种有前途的疗法。睾酮对高危人群生活质量、临床事件和安全性的益处,还需更充分有力的随机对照试验来评估。
90 Percent of Patients Want to Self-Manage Health Online: Accenture Survey
By: Brian T. Horowitz 2012-07-03 Patients want to access health information online and fill prescriptions electronically. But they also want face-to-face time with their doctor, a survey by Accenture revealed. Patients are interested in accessing health information electronically, but they don't want to give up regular visits to the office, according to a recent survey by consulting firm Accenture. For its Connected Health Pulse Survey, Accenture interviewed 1,110 U.S. patients between March 30 and April 4 to find out their preferences regarding digital health. It announced the results of its survey on June 20. Accenture interviewed patients to see how they wanted to communicate with doctors. It also looked into how patients perceived electronic health records (EHRs), the company reported. Of patients interviewed, 90 percent want to self-manage their personal medical data online, refill prescriptions electronically and book appointments on the Web, according to the report. The survey also found that patients were interested in using their mobile devices to refill prescriptions. Mobile apps such as LowestMed allow consumers to compare drug prices at their local pharmacies. Still, 85 percent of respondents preferred to see doctors in person when needed rather than relying on alternatives such as telehealth consultations. These results show that patients simply want multiple options to access care, according to Dr. Kaveh Safavi, head of Accenture's North America health industry group. "The survey shows that patients don't want an either/or scenario [regarding] in-person vs. online," Safavi told eWEEK in an email. "Instead, patients want access to more entry points into the health care system and the ability to customize options to address their specific needs." Patients are increasingly seeking "anytime, anywhere" access to their personal medical data, said Safavi. "But they're not willing to give up the option of face time with their physicians." Despite a large amount of respondents being interested in managing their health online, only 46 percent knew if they're data was already accessible online for tasks such as refilling prescriptions. Meanwhile, patients were split on whether to let doctors manage their EHRs or maintain the information themselves. Patients are interested in accessing their own test results online in a personal health portal, said Safavi. To manage their own health data, patients would need to use a service such as Microsoft HealthVault, which is available on mobile devices such as Windows Phone 7 and integrates with EHR applications like those from Greenway Technologies. Patients are also interested in learning about their conditions by using online educational resources. These sites include Aetna's iTriage, WebMD and the National Library of Medicine's MedLinePlus. Of patients surveyed, 72 percent want to be able to book appointments online. Although patients prefer face time with doctors over virtual visits, they still want to be able to email with their doctors, according to Accenture. According to the survey, 88 percent of patients are interested in email reminders of appointments and 76 percent would like to consult with their physicians through email. In addition, 74 percent want to be able to reach their doctor by phone. As far as which device to use to connect with their data, 73 percent of patients preferred mobile devices. "They appreciate the immediacy and convenience of digital resources, such as email and mobile devices, but still value in-person exchanges when needed," said Safavi.
美妝連鎖 不同的策略...寶雅
寶雅今年力拼總店數78家,全年獲利估增逾2成 2012/07/12 18:21 精實新聞 2012-07-12 18:21:07 記者 楊舒晴 報導 即使今年百貨零售業飽受消費力衰退之苦,主打平價消費策略的寶雅(5904)今年上半年累計營收仍達31.92億元,年增7.46%。到6月底為止,寶雅全台共有68家門市,目標今年底前力拼78家,預計下半年將再展10家門市,法人估計,全年營收將較去年成長1成,全年獲利可望較去年3.36億元約成長超過20%。寶雅為美妝及生活雜貨連鎖專賣店,產品包含括彩妝、服飾、雜貨、食品與藥品等,其中又以生活雜貨用品(服飾、雜貨、食品等)佔營收比重達68%,美妝佔29%、藥品佔3%,平均商品單價約70~80元間,客單價約370元,屬於平價消費,在目前經濟不景氣的環境下,營收還能維持成長。 截至6月底,全台總店數約68家,多以租金較低的大台北以外地區為展店區域,上半年只新展2家門市,下半年將會全力展店,力拼今年底前全台總店數達78家。 法人指出,寶雅展店地點大多不在精華區內,因此租金成本較低,再加上非精華區內百貨零售業較少,若寶雅開店都有相當的聚客力,新展門市約平均3個月即可轉盈,該公司今年目標新展12家門市,估計將帶動今年總營收較去年62.78億元約成長1成,全年獲利可望超過2成。 寶雅今(12)日進行除權息,每股配發現金股利3.28元、股票股利0.1元,除權息參考價為55.2元,市場看好該公司今年營收及獲利成長動能仍強,股價已經先行反應,昨日創下歷史新高達59元,但今日除權息後收在平盤55.2元。
Health-care apps for smartphones pit FDA against tech industry
David Paul Morris/BLOOMBERG - Applications for smartphones that check on blood sugar or allergies may face the same scrutiny from U.S. regulators as heart stents and defibrillators. The Food and Drug Administration plans to issue draft guidelines this year classifying mobile health tools for handheld computers such as Apple Inc.'s iPhone as medical devices. Text Size PrintE-mailReprints By Dina ElBoghdady, Published: June 22 Three tries. More than two years. And roughly $150,000. That's what it took for MIM Software to get the Food and Drug Administration's clearance for a smartphone application that physicians can use to view MRIs and other medical images. Ron Gutman is the CEO and founder of HealthTap, which creates mobile and Web applications with the goal of connecting individuals with medical professionals. Gutman spoke with the Washington Post's Emi Kolawole about the power of turning doctors into health care information curators for the Web and on mobile. "It was 2008 when we first tried," said Mark Cain, the Ohio firm's chief technology officer. "They didn't know what questions to ask and neither did we. . . . But at some point, they had to be thinking, 'How many more people will be lined up behind these guys?' " His was, in fact, among the first apps cleared by the FDA. And since then, medical applications have flooded onto millions of smartphones, offering consumers the chance to check their heart rate, identify a pill in their medicine cabinet or even scan moles for skin cancer. Soon, if a firm called AliveCor gets its way, they may even be able to get an EKG by pressing iPhone to chest.
The gee-whiz factor can both astonish and alarm. A defect in apps that essentially turn your phone or tablet into a medical device could prove problematic or even life-threatening: The app may not work as it should. For instance, what if lighting or contrast issues distort an X-ray that's viewed on an iPhone or iPad? That's why federal regulators lurched into action a year ago, offering their thinking on how to police this vast new frontier. Just as they were putting the finishing touches on a plan, lawmakers intervened. The Senate agreed to put the plan on hold after technology firms argued that heightened oversight would stifle innovation and cost jobs. On Monday night, a compromise was struck. Congress gave the FDA the green light to proceed with its push to define exactly which apps require its attention. But they also ordered the Obama administration to come up with a strategy that balances public interest with innovation in the years to come. The task is daunting, given the warp speed of technology. It's a classic showdown between Washington regulators charged with safeguarding the public's health and a free-wheeling tech industry that prizes agility and first-to-market bragging rights. "There are two completely different mind-sets," said Merrill Matthews, a resident scholar at the Innovative Policy Institute. "The app people think: Where is there a need and how do I fill it? And the FDA thinks: Where is there a problem and how can I control it?"
Cost-saving potential Mobile apps, with their extraordinary reach, have the power to transform health care. Half of cellphone users in the United States have smartphones such as the iPhone or Android software-based devices, which can deliver care to their hands and potentially do so at a lower cost. Using smartphones and wireless tablets as diagnostic tools or monitoring devices could also cut back on emergency room visits. For software developers, especially cash-strapped start-ups, there's an enormous amount riding on whether the FDA steps up enforcement — and exactly how it plans to do it, industry analysts said. "The FDA approval process adds months, if not years, and potentially millions of dollars to what it takes to bring a solution to the market," said Liz Boehm, a director at ExperiaHealth, a consulting firm. "That development process would put many of these guys out of business."Medical apps exploded onto the scene in 2010 and have grown by about 150 percent each year since, according to MobiHealth News, which tracks Apple's iTunes store, where many apps debut. Consumers can choose about 13,000 of these apps; 5,000 more are marketed to medical professionals. The offerings range from very basic — and free — apps that calculate body mass index to more sophisticated ones that make use of pricey supplemental devices. The pharmaceutical firm Sanofi has an app for diabetics that registers glucose levels with the help of a meter that attaches to iPhones. IHealth offers an app that records blood pressure using a cuff that plugs into an iPhone, and WiThing has one that tracks weight and body-fat percentage using the company's WiFi-enabled scale. Ron Gutman is the CEO and founder of HealthTap, which creates mobile and Web applications with the goal of connecting individuals with medical professionals. Gutman spoke with the Washington Post's Emi Kolawole about the power of turning doctors into health care information curators for the Web and on mobile. A survey by the Pew Internet Project found that 11 percent of adults with cellphones downloaded an app last year to help them manage their health. That same year, the mobile health-apps industry generated an estimated $718 million worldwide, seven times more than the previous year, according to Research2Guidance, a consulting firm.
The regulation debate While the FDA currently regulates certain medical software, the agency wants to update its thinking now that smartphones have juiced the apps market. A year ago, the agency proposed policing only a subset of those apps: ones that use supplemental attachments to transform a mobile platform into a medical device (such as AliveCor's EKG app) and others that act as accessories to an already regulated medical device (such as MIM Software's app). Rather than overseeing all medical apps, agency officials said they want to limit regulation to a slice of the market and take a pass on low-risk apps, such as calorie counters, according to Bakul Patel, an FDA policy adviser. "We are taking a proactive step by saying that from the FDA perspective," Patel said. "We're not concerned about all those other apps." Software makers, on the other hand, see an agency that currently regulates next to nothing in the mobile apps space taking a sudden interest in regulating more. The FDA proposal, they say, is vague and leaves many questions unanswered. For instance, given that apps can be updated daily, does a software developer have to seek FDA approval for each update? Among the critics is a group called the Health IT Now Coalition. It represents health-care providers, patient advocates and health insurance companies, including Aetna, which last year bought iTriage — an app that helps consumers evaluate medical symptoms and find the proper care. "The issue here is that they're really using a process for approval of these mobile apps that was basically created when the 5 ¼ floppy disk was the latest technology," said Joel White, the group's executive director. Dirk Hobbs, chief executive of Medical Voyce Sciences and Multimedia, said the FDA's plan is ambiguous and he doesn't know whether the apps his firm is developing would be regulated. The apps aim to speed communication among medical professionals in different facilities."This is just going to slam the brakes on an innovative sector that includes tons of small businesses like mine," said Hobbs, who expressed his concerns to Sen. Michael F. Bennet (D-Colo.). Bennet and Sen. Orrin G. Hatch (R-Utah) wrote a provision, inserted in a broader FDA funding bill, that would have delayed the FDA proposal by forcing the agency to first reach agreement with other regulators about how to handle these apps. This week, in a compromise reached by House and Senate lawmakers, Congress allowed the FDA to press ahead. But it also directed the agency to work on a report with other regulators that would lay out an appropriate framework to promote innovation and protect patient safety. Former FDA deputy commissioner Scott Gottlieb, who researches medical trends as a fellow at the American Enterprise Institute, said he's disappointed. If consumers can track their blood-sugar levels using pen and paper, he said, why should the government have to clear an app that does the same thing more reliably? Gottlieb said that software developers should be suspicious because regulators have a tendency to tighten their grip on industries as they develop. "If they perceive a power vacuum," he said, "they'll step in and regulate more and more."
Some seek guidance Some in the tech industry do not perceive a threat. They say they've been expecting the FDA to regulate some apps and are eager for the agency to reveal which ones. A group called the mHealth Regulatory Coalition — which represents established firms such as Qualcomm as well as start-up software developers — was formed in 2010 to deal with mobile health care regulatory issues. Its leaders argue that uncertainty breeds anxiety and drives away potential investors. "We started telling the FDA that they're going to stifle innovation if they don't start clarifying where the lines will be drawn," said Bradley Thompson, the group's general counsel. Other technology groups — including the West Wireless Health Institute and the Application Developers Alliance — have taken a similar position. In a recent meeting with industry representatives, Jeffrey E. Shuren, head of the FDA's Center for Devices and Radiological Health, assured the group that the final plan would include more details than the draft, some attendees said. The agency may even create a Web site with generic examples of apps that would be exempt, Shuren told them. In the end, the FDA's plan may indeed sink some software makers whose products can't withstand federal scrutiny, said Lisa Suennen, co-founder of Psilos Group, a health-care-focused venture capital firm. "But while regulation puts an extra burden on young companies, those that can get through it will have a huge competitive advantage," Suennen said. "You can't have every Tom, Dick and Harry claiming that their medical app adds value without having to prove it."
化療新方向TMPK抑制劑可專殺癌細胞
鉅亨網新聞中心(來源:華人健康網)2012-07-19 14:06:24華人健康網 記者張世傑/台北報導國內基礎醫學研究又有重大發現!陽明大學生物化學暨分子研究團隊,在大白鼠動物實驗中,找到攸關癌細胞生長的TMPK標靶酵素,且據此發展出一個小分子抑制劑YMU1,可達到只針對癌細胞有毒殺作用,不會對正常細胞造成影響,此研究提供未來降低副作用癌症化學治療的新方向,成果發表於今年7月10日的國際知名醫學期刊「CANCER CELL」。主導這項研究的陽明大學生物化學暨分子研究所教授張智芬指出,國內10大死因中,癌症高居不下,許多病友在癌症化療後,常因正常組織受到抗癌藥物的侵襲傷害,造成非常不適的副作用,例如噁心、嘔吐等。因此,發展一個溫和的化療藥物組合內容,只針對癌細胞有毒殺作用,而對正常分裂細胞的影響很小,將對病人的治療過程會有極大的益處。目前,有許多傳統的化療藥物,其作用機轉是透過造成DNA嚴重損害以達毒殺細胞的效果,但這種DNA損害作用,同時也會對正常組織中快速生長的正常細胞造成毒害,也可能促成細胞二度癌化。這些副作用當然可以藉著降低藥物劑量獲得改善,但癌細胞卻可藉著DNA修復得到喘息的機會,最後造成治療失效。張智芬表示,由於細胞在DNA修復時,需要去氧核醣核苷酸做為原料之供給,研究團隊分析癌細胞及正常分裂的細胞,在接受少量DNA損害後,細胞去氧核醣核苷酸代謝的分歧性,結果發現癌細胞在少量DNA受損後,其核醣核苷酸還原酶表現量增多,同時配合胸腺核苷酸激酶(TMPK)之作用,產生足夠且平衡的4種去氧核醣核苷酸,進行DNA修補,使細胞得以繼續生長。但在降低TMPK的酵素活性後,造成4種去氧核醣核苷酸不平衡,使得DNA修補不完整,而癌細胞由於DNA基因不正常,因此形成分裂死亡。張智芬教授強調,在大白鼠動物實驗中,找到能有效抑制癌細胞生長的TMPK標靶酵素,且不會對正常細胞造成影響的小分子抑制劑YMU1。˙相對地,正常分裂細胞在少量DNA遭受損傷後,其核苷酸還原酶表現量下降,細胞呈現休止狀態,即使在TMPK功能下降情況下,其4種去氧核醣核苷酸仍保持平衡,使得DNA修復仍可完善進行,直至DNA的受損修補完整,因此,不會形成分裂死亡。 張智芬強調,在這樣的研究基礎下,研究團隊以TMPK為新標靶,利用冷光快速篩選系統,發展出第一個TMPK抑制劑酵素,可以專一性降低胸腺核苷三磷酸(dTTP)之生成,配合低劑量的化療藥物─小紅莓(Doxorubicin),可以有效毒殺癌細胞,而不對正常分裂的細胞產生毒害。同時從21,120個化合物中,發現第一個可穿透細胞的人類胸腺嘧啶核酸激酶(hTMPK)小分子抑制劑,命名為YMU1;實驗證明發現,低劑量的小紅莓合併YMU1並不會對正常細胞或組織造成影響,但可以有效抑制多種癌細胞的生長,在小鼠身上也會顯著減緩腫瘤的形成。
Happtique Mobile Health App Draft Guidelines Are Available
By: Brian T. Horowitz 2012-07-13 Happtique has published a draft of its mobile health app guidelines and seeks feedback from the medical community. Happtique, which runs a marketplace for mobile health applications, has released its draft guidelines on medical app development. Described as a "Good Housekeeping" seal of mobile apps by Happtique CEO Ben Chodor, the App Certification Program specifies which types of apps satisfy standards on operability, privacy, security and content, the company reported. Happtique is a unit of GNYHA Ventures, the business arm of the Greater New York Hospital Association. It launched the App Certification Program Jan. 17 and released its draft on July 11.
The draft dictates that apps need to operate reliably, according to Chodor. "There are tens of thousands of medical, health and fitness apps on the market, and their sheer number makes it difficult for health care professionals and consumers to locate apps that operate reliably, are based on valid information and safeguard users' information," Chodor said in a statement. "Happtique's App Certification Program will address an important need in the m-health field by evaluating apps along these dimensions." In a similar process, the FDA published its guidelines on medical health apps in July 2011. The FDA plans to regulate apps that work as accessories to FDA-regulated devices or that turn smartphones into medical devices to monitor conditions such as abnormal heart rhythms. Happtique's operability standard would mandate that apps run effectively on mobile devices, and are able to connect properly to peripherals as well as WiFi or cellular networks. Speed would also fall under operability standards, though the document doesn't mention how fast an app would need to operate on a network. To satisfy the privacy standard, a mobile app would have to make clear who will receive a patient's information prior to the user downloading the software. The app also must disclose resources that would be used, including how many Short Message Service (SMS) or Multimedia Message Service (MMS) messages would be sent per month, how many emails would be sent and which Bluetooth profiles would be used. As far as security, mobile apps would need to ensure that they don't contain viruses, worms, spyware, adware, rootkits or other threats. The content standards would require that the app is current and gets its data and documentation from a "recognized source." In addition, content would be need to be written in layperson's terms, according to Happtique. A panel of experts made up of a doctor, nurse, biotechnology scientist and patient advocate developed the guidelines. Happtique is looking for feedback from the medical, health and fitness community, including app owners, developers and patients, according to Dr. David Lee Scher, chair of Happtique's App Certification Program Blue Ribbon Panel. "Our goal is to produce a set of rigorous standards that will give both health care professionals and consumers a solid basis for selecting apps," Scher said in a statement. "We believe the certification process will lead to the identification of truly high quality apps, thereby giving health care professionals and consumers alike the confidence they need in the apps they are recommending or using," said Chodor.
南部生技醫材產業聚落 生技月搶眼!!
101年第十屆台灣生技月參展7/26至29登場2012-07-19 17:15:52 蔡清欽/報導生技產業是南部科學園區重點發展的產業之一,南科管理局為了讓社會大眾能了解南科生技產業的發展現況,因此邀集區內生技產業廠商,包括金穎生物、和鑫生技、双美生物、皇亮生醫、東宇生物、美梭生技、京達醫材、鴻君科技等八家廠商,於7月26至29日在台北世貿展覽一館舉辦的2012台灣生物科技大展中,設置南科主題館共同參展。近年來隨著社會邁向高齡化,對醫療器材的的相關需求也大幅成長,未來醫療器材產業將呈現高成長的發展趨勢。南科管理局發展重點,也由生技產業拓展至生技醫療器材的發展,自98年起執行「南部生技醫療器材產業聚落發展計畫」,迄今已邁入第4年,不僅吸引國內外知名廠商進駐園區,同時亦展現了豐碩成果。除引進醫材廠商投資進駐南科外,目前已引進13所學校及研究機構於園區內設置研發中心,除可藉由整合學術量能來培育高階生技醫材產業專業人才,進而提升產業競爭力外,並可協助廠商開發高階醫材產品與技術,以建立國內醫療器材自有品牌產品,提升台灣醫療技術水平及國際形象,奠定台灣生技醫療器材產業穩固發展之基礎。秉持「立足亞太,放眼世界」的精神,南科將持續推動醫療器材產業聚落發展,預計計畫完成後將創造百億元商機,屆時必能藉由聚落綜效,加速與各國合作的機會,進而使南科成為世界級的生技醫療器材產業重鎮。【中央網路報】
醫藥新興市場區塊 3,000億美元市場規模!!!!!
生技醫療基金 題材多 2012/07/19 【經濟日報╱記者高佳菁/台北報導】 今年股市慘遭歐「傷」下挫,讓具備防禦色彩的生技醫療類股逆勢追漲,NBI生技指數今年以來上揚28.58%,7月初甚至一度逼近1,400點大關,隨著7月下旬生技股季報公布進入高峰,9月接著進入醫學年會及傳統旺季,加上併購題材不斷,相關生技醫療基金漲勢可期。ING全球生技醫療基金經理人黃靜怡表示,美國進入第2季財報公布期,生技類股走勢難免受財報表現左右,如本周有包含製藥大廠嬌生、亞培,以及醫療設備大廠百特醫療等企業將公布財報,7月下旬則有Biogen Idec、Amgen、Celgene等生技權值股加入行列,財報表現值得關注。富蘭克林坦伯頓生技領航基金經理人麥可羅指出,根據花旗集團預估,美國大型生技股2012~2014年獲利年增率預估值介於13%~15%,高於史坦普500大企業4%~6%增幅。黃靜怡認為,全球生技醫療類股產業基本面與總體經濟環境連動性偏低,在系統性風險升高之際,反而易吸引資金青睞;其次,今年上半年釋出之新藥研發結果,高達75%為正面,更重要的是9月開始進入醫學會議密集召開期,且第4季向來為生醫傳統產業旺季,預期下半年該類股仍可望震盪走高。德盛安聯全球生技大壩基金經理人傅子平進一步指出,近期市場偏重在具被購併條件與藥物研發和上市時程接近後段的公司,目前較看好此波大型製藥公司購併中小型生技公司的趨勢,預期在專利藥專利到期的壓力與低利率環境下,購併案將延燒至2013年。著眼新興市場受惠於中產階級成長、醫療涵蓋範圍擴張、每人藥品支出水準仍低、生活型態改變和慢性病增加等結構性因素,對醫療的需求成長潛力相當龐大,麥可羅認為,涵蓋金磚四國、南韓、土耳其與墨西哥等7國的醫藥新興市場的藥物支出占全球市場的比重,於2010年已正式超越歐洲5大國(法國、德國、義大利、西班牙、英國),成為僅次於美國的全球第2大支出區域,預估2015年醫藥新興市場的藥物支出金額有機會突破3,000億美元,成長潛力相當雄厚。
REVOLUTIONARY DRY SKIN TREATMENT SUCCESSFULLY OVERCOMES THE PROBLEM OF ECZEMA
Saturday, 14 July 2012 Revolutionary dry skin treatment protects your skin from the itch of eczema.
What is the underlying cause of eczema? Eczema is a chronic skin disease characterized by dry, itchy, inflamed skin caused by an allergic immune response with in the skin. While there is no cure for the condition, understanding the causes and finding the right dry skin treatment product can greatly reduce the occurrence of symptomatic outbreaks and how to rejuvenate skin.
Could you be suffering from a damaged skin barrier? Nearly 80 percent of eczema is due to contact with harsh chemicals and environmental irritants. If you have damaged dry skin your skin's barrier is impaired and no longer properly functions and an increase in water loss having dry and cracked skin. Besides an increase in water loss, a damaged skin barrier makes your skin more susceptible to irritants that create an increased risk for dry skin conditions such as eczema. "As a dermatologist with many years of experience treating skin problems, I can tell you what the major causes are," says Dr. Lisa Benest, "one of them is exposure to irritants and chemicals in the everyday environment. We live in a much more toxic environment today and our skin bears the brunt. When we are exposed to harsh conditions in the environment it can have a very negative effect on our skin."
Shielding Lotion: A Revolutionary New Dry Skin Treatment that is the Best Lotion for Dry Skin Traditional moisturizers are simply add artificial moisture to the surface layer of your skin and do very little to heal or protect your skin. Many even contain harsh chemical ingredients that damage the integrity of your skin's barrier leading to more skin problems for you. Realizing the need for an entirely new approach to skin care, 21st Century Formulations put together a team of leading doctors, dermatologists, and cosmetic chemists who spent six years working together in developing Skin MD Natural Shielding Lotion. Skin MD Natural Shielding Lotion duplicates your skin's own natural functions and strengthens your skin's ability to protect against toxins and irritants resulting in healthier softer skin. Dr. Lisa Benest explains: "The reason shielding lotions are so effective is that they replace the protective barrier and allow the skin to heal from within. A shielding lotion bonds with the outer layer of the skin and protects it from outside irritants and chemicals, so it will prevent skin conditions from developing or it will help an existing condition to heal." Join the millions throwing away their old creams and lotions for Skin MD Natural: It's the only lotion that can truly treat severe eczema and is a real dry skin treatment. Go to http://www.skinmdnatural.com or call 800-540-4790 for more information. 21st Century Formulations is a company dedicated to creating healthy skin care shielding lotions. For more information please contact 1-800-540-4790.
講究 "就診秩序 "的日本醫療體系 !
國際SOS:中國醫療品質仍待改進 台灣醒報實際入稿日期: 2012-07-19【台灣醒報記者劉運台北報導】中國及日本是台灣人近2年最喜歡旅遊的國家,但國人還是不熟悉國外的醫療制度。國際SOS緊急救援組織指出,即使中國的醫療體系持續改善,但是其人口眾多,仍然無法負荷廣大的人口需求,造成醫療品質的下降。相較之下,日本的醫療體系完善,國人比較可以放心就醫。國際SOS緊急救援組織指出,台灣人在國外就診主要是因為腸胃相關疾病、呼吸道相關疾病,及外傷(扭、挫、骨折);最常就診的年齡層依序為36-55歲(43%),56-75歲(41%),16-35歲(14%)。在過去2年,最多國人前往的國家分別為中國(約58%)及日本(約13%)。 國際SOS緊急救援組織指出,即使中國一直在努力改善提升醫療品質,但中國的醫療體系仍然追不上中國廣大的人口需求。醫師陳琬琳指出,因為人滿為患,中國的醫院甚至出現VIP病房移至走廊上、病人的病床座位相隔距離太近,造成容易傳染疾病、沒有隱私的問題。另外,病房內環境欠佳、燈光昏暗,也會讓國人心生恐懼。 陳琬琳指出,中國的3級醫院硬體規模大、有幾千個床位,醫療人員也有一定的醫療水準,但也有許多缺失:由於中國人口眾多,經常有醫院門診大廳擠得水洩不通的情況,甚至有「門診黃牛」的現象,亦即有人提早來排隊領取號碼牌再轉而販售,價格是掛號費的5-6倍,若是名醫價碼則更高。 相較於中國,日本的醫療品質就讓人放心許多,但是有別於國人的看病習慣,日本的醫療體系非常講究「就診秩序」,看診有一定的流程。國人常把在台灣不好的看病習慣帶到日本,例如催促醫生、亂跑診間等問題。陳琬琳指出,如果去日本的醫院,應該多多注意,遵守當地的看病流程。
Current development of regenerative medicine products!!
Leading the way Business Posted on 18/07/2012 by Lorraine O'Hanlon @galwayindoThe global market potential for regenerative medicine products could be as high as $118 billion by 2013 and innovative Galway company Orbsen Therapeutics is working to target part of this rapidly expanding market, CEO Brian Molloy tells Lorraine O'Hanlon Earlier this year, US company Osiris Therapeutics received authorisation from the Canadian department of health to market its stem cell therapy Prochymal for the treatment of acute graft-versus-host disease in children who have received bone marrow transplants, marking the world's first regulatory approval of a manufactured stem cell product. Referring to the move as an important domino in the acceptance and development of stem cell therapies, Orbsen Therapeutics CEO Brian Molloy explains that adult stem cells appear to display an ability to combat inflammation and to promote healing and the repair and regeneration of tissue. "What that means is that if you have an inflammatory disease, for example rheumatoid arthritis, or when there's an inflammation of a particular organ or area of the body, stem cells seem to help calm down that inflammation" he says, adding that there are hundreds of ongoing trials across the world where stem cells are being used to treat a wide range of different conditions currently not being adequately treated by traditional drugs. There are currently up to 400 regenerative medicine products on the international market, with more in development. At NUI Galway, Orbsen Therapeutics is working on the development of an extensive range of therapies for conditions including osteoarthritis, acute respiratory distress syndrome and diabetes. Formed in 2006 to develop and commercialise new intellectual property built up by researchers at the Regenerative Medicine Institute (REMEDI), Orbsen has developed a novel proprietary technology enabling them to isolate pure and defined stromal cells, which it is hoped will allow the development of a range of human therapies. Led by Head of R&D Dr Stephen Elliman, the company is currently expanding rapidly and the number of employees is expected to increase to around ten by the end of the year. It is also hoped the company will begin clinical trials in 2014. The development of spin out companies from universities can be difficult, according to NUI Galway MBA graduate Mr Molloy, as a marrying of both business and scientific skills is required. He believes, however, that Orbsen is proving to be a "very good model for how you can bring university generated research into a commercial field by partnering up with commercial experts in the private field". Mr Molloy is a Director of financial advisory firm HC Financial Advisers, based in Oranmore. HC provide a range of business consultancy services to start-up and established firms and Mr Molloy serves as Orbsen Therapeutic's interim CEO under a business consultancy arrangement. NUI Galway remains a shareholder in the company and Mr Molloy explains that the business model for the privately owned company is very lean compared to the old style model of commercialisation of university developed spin outs, which would have involved "a very significant amount of capital being spent on getting the company up to a certain level of critical mass". He adds that it's much more difficult at the moment to source money than it had been in previous years, and that the focus now for start-up biotech companies such as Orbsen Therapeutics is really on keeping the operational costs as low as possible and "focus on the science". Despite the difficult economic climate, Orbsen's bids to secure funding over the years have proven very successful. The company will shortly commence a new round of fundraising and is currently seeking High Potential Start-Up status from Enterprise Ireland. The company has also secured significant EU funding and is lead SME on a EU Seventh Framework Programme (FP7) research initiative on diabetic complications. €6 million has been allocated to bring Orbsen's novel therapy to clinical trial in collaboration with leading researchers within NUI Galway and across Europe and the US. "There are a huge number of illnesses and conditions where having an anti-inflammatory and immunomodulating product is of massive importance, that's why billions are being spent by 'Big Pharma' and international biotech companies to develop into this space. "Orbsen is ideally positioned because we are in the process of securing our IP [intellectual property] around our subpopulation of cells, we are in compliance with the emerging future regulatory requirements with regard to purity and definition of our cell product and we're doing it at a relatively low cost whilst leveraging the really high quality research coming out of NUI Galway," he says, adding that two of REMEDI's directors, Prof. Timothy O'Brien and Prof. Frank Barry, are also directors at Orbsen."As well as a multi-billion euro market potential there is also the added value of knowing that if our product delivers as we hope it will, it has the potential to improve and save people's lives," says Mr Molloy.